GTCM
MRTX

Gyon Technologies Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Gyon Technologies Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,581
Closed -$208K – 466
2022
Q4 		$208K Buy
+4,581
New +$296K 0.08% 295
2021
Q2 		– Sell
-3,035
Closed -$520K – 517
2021
Q1 		$520K Buy
+3,035
New +$601K 0.23% 153

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Gyon Technologies Capital Management's MRTX Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2023, closing a stake of 4,581 shares — an estimated $208K sold.

Gyon Technologies Capital Management first reported a position in MRTX in Q1 2021 and held it in 2 quarters. The position peaked at $520K in Q1 2021. 221 funds tracked by Wall St. Rank hold MRTX as of Q1 2023.

  • Gyon Technologies Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 4,581 Mirati Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $208K.
  • Gyon Technologies Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Gyon Technologies Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $520K in Q1 2021.
  • 221 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.